[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigación Sanitaria Aragón\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":282},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,75,88,118,150,182,209,236,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054032","development-and-effectiveness-of-the-participatory-adapted-3d-sedentation-system-ssap3d-100054032",false,"NCT07330921","Development and Effectiveness of the Participatory Adapted 3D Sedentation System (SSAP3D).","Development and Effectiveness of the Participatory Adapted 3D Seating System (SSAP3D) and Its Impact on the Daily Performance of Children With Neuromotor Dysfunction and Their Families: Pilot Study","SSAP3D","Inclusion Criteria:\n\n* Medical Situation of Neuromotor Disfunction\n* Be user of some type of adapted seating system\n* Age between 2-6 years\n* Have head control levels of 3 to 8 on the Level of Sitting Scale (LSS)\n* Be able to maintain a standing position for at least 10 seconds, with or without external assistance.\n\nExclusion Criteria:\n\n* Presenting moderate or severe cognitive impairment, which generates significant difficulties in understanding the instructions given by the evaluator\n* Having suffered a traumatic injury o surgical process in the 6 months prior to the start of the study or during the study","ALL","2 Years","6 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","Problems with postural control cause difficulties in children's motor development, leading to significant structural and functional complications, including pelvic obliquity, scoliosis, and asymmetries in both active and passive ranges of motion. All these difficulties affecting posture control have a negative impact on children's functional autonomy and independent participation in their daily activities, as well as on their interaction with different environments, mainly family, social, and educational. In view of this situation, the 3D Adaptive Sitting System \"SSAP3D\", a 3D pelvic ser with a self-extracting abductor cushion, is proposed as an alternative.\n\nThe main objective is to develop and test a novel 3D-printed adaptive seating system, called SSAP3D, tailored to individual needs of children with Neuromotor Dysfunction, to assess whether it promotes the functional performance of children in their daily and meaningful activities.\n\nA secondary objective is to analyze whether the use of SSAP3D promotes the children's participation in different environments compared to a conventional seated system.\n\nThe sample is estimated at 12 children, all of them were between 2-6 years old and with Neuromotor Dysfunction from early attention centers, as well as from private rehabilitation centers or associations.\n\nThe intervention program will be the same for each participant, but in different temporal order. 6 children will use during the first 6 weeks the 3D seat and the following 6 weeks their usual seating system; the others 6 children inverted order. The 3D seat will be made individually for each child. The device will be delivered 3 weeks after the scanning-data collection accompanied by guidelines for use. There will be 2 online follow-up sessions.\n\nHypothesis: the implementation of the SSAP3D allows to ensure the postural requirements of children with Neuromotor Dysfunction and to favor their functional performance in daily and meaningful activities at home, at school and in their community. In addition, it will have a positive impact on the quality of life perceived by the families related to the characteristics of the seat.",[28],"Neuromotor Dysfunction",[30,31,32,33,34],"Performance","Children","Seating System","3D Technology","Quality of Life","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-04-03",{"date":43,"type":22},"2026-10-30",{"name":45,"class":46},"Instituto de Investigación Sanitaria Aragón","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100425751","effects-of-unicla-a2-dairy-products-on-patients-at-high-risk-of-colorectal-cancer-development-100425751","NCT04824053","Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development","Comparative Analysis of the Effects of UNICLA-A2 Against Conventional Dairy Products Administered Daily in Patients at High-risk Colorectal Cancer Development Who Have Undergone Polypectomy","Inclusion Criteria:\n\n1. Participants diagnosed with high-risk polyps in the colorectal cancer screening programme or in the relative's colon cancer prevention program or patients who are in follow-up due to prior detection of polyps with any of the following characteristics:\n\n   * At least 10 adenomas\n   * At least 5 proximal serrated polyps (PSP)\n   * At least 2 serrated polyps with diameters ≥10 mm\n   * Serrated Polyposis Syndrome (SPS)\n   * Early invasive CRC (stage pT1) endoscopically resected (surgery not required)\n   * A sessile or flat lesion ≥ 20 mm with fragmented resection\n   * Patients with previous resection of polyps in which the resection margin was not assessable and are considered susceptible to repeat colonoscopy\n   * Patients with intramucosal carcinoma in situ or invasion of the lamina propria (pTis)\n2. Regular consumer of milk and dairy products.\n3. Informed consent form signed.\n\nExclusion Criteria:\n\n1. History of allergic reaction attributed to compounds of similar chemical composition to the study agents.\n2. Incomplete colonoscopy or with poor quality criteria, Boston \\\u003C6.\n3. Concomitant acetylsalicylic acid (ASA), NSAIDs, misoprostol, corticosteroids or statins needed on a regular or predictable basis during the time of the study.\n4. Previous gastrointestinal surgery (colon or small intestine or gastric) that affects the absorption of nutrients.\n5. History of familial adenomatous polyposis.","18 Years","80 Years",{"count":58,"type":22},34,[25],"Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy",[62],"Colorectal Polyp",[64,65,66],"polyp","inflammation","fecal microbiota","2026-05-08",{"date":69,"type":39},"2026-05-12",{"date":71,"type":39},"2022-02-28",{"date":73,"type":22},"2028-12-15",{"name":45,"class":46},{"id":76,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":26,"conditions":79,"keywords":80,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":47},"100618384",{"count":21,"type":22},[25],[28],[30,31,32,33,34],"2026-03-31",{"date":83,"type":39},"2026-04-06",{"date":85,"type":22},"2026-04",{"date":43,"type":22},{"name":45,"class":46},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":95,"targetDuration":97,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":47},"100607196","spanish-registry-of-redo-procedures-following-pulmonary-vein-ablation-by-pulsed-field-ablation-technology-reset-pfa-100607196","NCT07185412","Spanish Registry of Redo Procedures Following Pulmonary Vein Ablation by Pulsed Field Ablation Technology: RESET-PFA","RESET-PFA","Inclusion Criteria:\n\n* Patients with an indication to a pulsed-field ablation procedure of Atrial Fibrillation according to current international and local guidelines (and future revisions), existing IFU or per physician discretion\n* Patients who are willing and capable of providing informed consent, participating in all testing at an approved clinical investigational center or such consent will be provided by a legal representative, if required by local law or regulation.\n\nExclusion Criteria:\n\n* Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments\n* Patients who are unwilling or unable to sign an authorization to use and disclose health information or an Informed Consent.\n* Patients unavailable or not willing to complete follow up visits and examination for the duration of the study at the center.\n* Life expectancy ≤ 12 months per physician judgment.",{"count":96,"type":22},1100,"1 Year","OBSERVATIONAL","RESET-PFA is a prospective, multicenter, non-randomized post-market study. All patients will be treated according to the standard care followed by each center. The protocol requires enrollment of consecutive patients from each center, according to eligibility criteria. During the 12 months follow-up period, clinical atrial fibrillation recurrence, occurrence of all kinds of atrial arrhythmias and of all Adverse Events in the study population will be collected.\n\nThe purpose of this study is to prospectively evaluate during time a large population of patients with an indication for ablation of AF, collecting data on procedural success in the acute and medium- to long-term follow-up. The primary objective of the study is the determination of up to 10 clinical and procedural parameters predicting a repeat ablation procedure after the blanking period in patients that had undergone an AF ablation with pulsed field ablation through a standard of care pathway.",[101,102,103],"Cardiac Arrhythmia","Atrial Fibrillation","Pulsed Field Ablation",[103,105,106,107,108],"Atrial fibrillation","Pulmonary vein isolation","Redo procedure","Mapping system","NOT_YET_RECRUITING","2025-09-15",{"date":112,"type":39},"2025-09-22",{"date":114,"type":22},"2025-10-01",{"date":116,"type":22},"2030-12-31",{"name":45,"class":46},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":134,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":47},"100598364","unified-protocol-in-penitentiary-facilities-100598364","NCT07070531","Unified Protocol in Penitentiary Facilities","Feasibility and Clinical Utility Study of the Unified Protocol for Group Treatment of Emotional Disorders in Penitentiary Facilities","Inclusion Criteria:\n\n* At least one emotional disorder diagnosis (e.g., anxiety, depression, OCD, trauma-related, somatic, dissociative) based on the MINI interview\n* Comprehension of the intervention language (Spanish or Catalan)\n* Substance abstinence for more than 1 month\n* Voluntary participation and availability for all assessment and treatment sessions\n* Stable pharmacological treatment during the study unless medically contraindicated\n* Signed informed consent\n\nExclusion Criteria:\n\n* No emotional disorder diagnosis\n* Cognitive impairment or IQ \\\u003C70 preventing comprehension\n* Diagnosis of a mental disorder incompatible with group formats (e.g., histrionic personality disorder)\n* Suicide risk at assessment\n* Legal status involving potential release or leave that could affect adherence",{"count":126,"type":22},25,[25],"Emotional disorders (EDs), which include anxiety disorders, unipolar mood disorders, and other related conditions, exhibit a high prevalence within prison populations, significantly exceeding that of the general population. Despite the high incidence of these disorders, the resources available for their treatment in correctional facilities are limited. The shortage of both human and material resources hinders inmates' access to quality mental health care.\n\nIn this context, the Unified Protocol (UP) for the transdiagnostic treatment of emotional disorders, a transdiagnostic intervention grounded in Cognitive Behavioral Therapy, has demonstrated effectiveness in addressing a variety of psychological problems across different contexts. It has also proven to be cost-effective, particularly when delivered in a group format. Therefore, implementing the UP in group format within correctional settings could represent a viable strategy to optimize limited resources and provide accessible and effective treatment to a larger number of inmates.\n\nThe primary objective of this pilot study is to evaluate the feasibility and clinical utility of the UP for the treatment of emotional disorders in prison environments. To this end, the UP will be delivered to approximately 25 participants, organized into groups of six to eight individuals, each receiving 12 weekly sessions lasting one hour. Follow-up assessments will be conducted at one, three, and six months after the intervention.\n\nA mixed-methods approach will be employed to analyze the results, combining quantitative analyses to assess changes in emotional symptomatology and qualitative analyses to explore participant satisfaction and therapist acceptance. It is expected that participants will experience statistically significant improvements in emotional symptoms and that these improvements will be sustained over time, up to the six-month follow-up. It is also anticipated that participants will report a high level of satisfaction with the treatment. Furthermore, therapists are expected to evaluate the intervention positively and to identify potential barriers to its implementation.\n\nThe results of this pilot study will contribute to improving the feasibility and clinical utility of the UP in correctional settings, while also laying the groundwork for a future randomized controlled trial involving a larger number of facilities, participants, and therapists.",[130,131,132,133],"Depression Disorders","Anxiety","Mood Disorders","Emotional Disorder",[135,136,137,138,139,140,141],"Unified Protocol","Transdiagnostic Intervention","Incarcerated Population","Correctional Facilities","Group Therapy","Cognitive-behavioral Therapy","Emotional Disorders","2025-07-16",{"date":144,"type":39},"2025-07-17",{"date":146,"type":22},"2025-11-01",{"date":148,"type":22},"2026-07-01",{"name":45,"class":46},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100593586","phase-3-the-role-of-intraabdominal-pressure-and-point-of-care-ultrasound-to-guide-decongestive-therapy-in-heart-failure-100593586","NCT07008365","The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure","ABDOPOCUS-HF","Inclusion Criteria:\n\n* Men or women over 18 years of age.\n* Diagnosis of heart failure (HF) based on the latest HF guidelines published in 2022.\n* N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 1000 pg\u002FmL or Brain Natriuretic Peptide (BNP) \\> 250 pg\u002FmL.\n* Placement of a urinary catheter to allow for the measurement of intra-abdominal pressure.\n* Intravascular or mixed congestion pattern, defined as the presence of one or more clinical signs of congestion (edema, ascites, and\u002For pleural effusion).\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient with a stay in the Internal Medicine department \\> 24 hours.\n* Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization).\n* Patient\\'s refusal to participate in the clinical trial.\n* Inability or contraindication for urinary catheter placement.\n* Systolic blood pressure at admission \\< 100 mmHg.\n* Heart rate at admission \\> 170 beats per minute (bpm).\n* Cardiogenic shock.\n* Acute myocardial ischemia.\n* Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).\n* Kidney transplant recipients.\n* Serum hemoglobin \\< 9 g\u002FdL.\n* Pregnancy or breastfeeding.\n* History of hypersensitivity to hydrochlorothiazide or furosemide.\n* Patients admitted from the Intensive Care Unit.\n* Patients with recent cardiac surgery (within the last year) or heart transplant recipients.\n* Need for inotropic support to maintain adequate cardiac and\u002For renal output.","100 Years",{"count":159,"type":22},168,[161],"PHASE3","Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.",[164,165,166,167],"Acute Heart Failure","Congestive Heart Failure","Intraabdominal Hypertension","Cardio-Renal Syndrome",[169,164,170,171,172],"Point of care Ultrasound (POCUS)","Cardio-renal syndrome","Intraabdominal pressure","Diuretic treatment","2025-06-04",{"date":175,"type":39},"2025-06-06",{"date":177,"type":39},"2025-03-10",{"date":179,"type":22},"2026-12-31",{"name":45,"class":46},2,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":208,"locationsCount":181},"100587445","effectiveness-and-acceptability-of-the-unified-protocol-for-the-transdiagnostic-treatment-of-emotional-disorders-in-people-with-long-covid-19-100587445","NCT06928480","Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.","UP-LONGCOVID-R","Inclusion Criteria:\n\n* Residing in Autonomous Community of Aragon (Spain).\n* Being at least 18 years old.\n* Understanding of Spanish.\n* Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection.\n* Symptoms of depression (ODSIS≥7) and\u002For anxiety (OASIS≥8).\n* Meeting the criteria for an emotional disorder diagnosis.\n* Having access to Internet.\n* Signing the informed consent.\n\nExclusion Criteria:\n\n* Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection.\n* Actually receiving psychological treatment.\n* Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.).\n* Active suicidal ideation at the time of the assessment.\n* Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.",{"count":190,"type":22},90,[25],"This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain.\n\nIn this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.",[194,133,131,130,195],"Long Covid-19","Emotion Regulation",[197,141,198,135,199,200,201],"Long COVID-19","Emotion regulation skills","Transdiagnostic","Psychological","Cognitive Behavioral","2025-05-19",{"date":204,"type":39},"2025-05-22",{"date":206,"type":39},"2025-05-01",{"date":179,"type":22},{"name":45,"class":46},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":47},"100558156","unified-protocol-for-treatment-of-emotional-disorders-in-brief-groups-in-primary-care-services-in-spain-100558156","NCT06547450","Unified Protocol for Treatment of Emotional Disorders in Brief Groups in Primary Care Services in Spain","Study of the Cost-efficacy and Acceptability of the Unified Protocol for Treatment of Emotional Disorders in Brief Groups in Primary Care Services in Spain (PU-AP)","Inclusion Criteria:\n\n* Have at least one EDs diagnosis (anxiety, depressive, obsessive-compulsive, trauma and somatic disorders) from the ADIS-5 interview\n* Have a score between 0 and 5 severity (mild-moderate) on the diagnoses on the CSR of the ADIS-5\n* Be able to attend all assessment and treatment sessions\n* Individuals on pharmacological treatment will be asked to maintain the dosage for the duration of the study, unless there is a medical contraindication\n\nExclusion Criteria:\n\n* Absence of clinical diagnosis\n* Presenting a diagnosis of EDs with a severity score on diagnoses between 6 and 8 on the ADIS-5 CSR (severe) or a clinical condition requiring specialized mental health intervention such as presence of severe mental disorder (e.g., personality disorder, bipolar disorder, or schizophrenia), suicide risk at the time of assessment, or substance use in the past three months\n* Who have received 8 or more sessions of CBT (during the past five years) with techniques such as cognitive flexibility or exposure\n* Who are receiving psychological treatment.",{"count":217,"type":22},180,[25],"The aim of this project is to contribute to the improvement of psychological care received in primary care (PC), through the study of the cost-effectiveness and acceptability of the Unified Protocol for the treatment of emotional disorders in brief groups in primary care services in Spain (PU-AP) for the treatment of emotional disorders (EDs), the most prevalent in our society. To do so, a pilot study will be carried out, and, subsequently, a randomized clinical trial to study the efficacy, cost-effectiveness and acceptability of the Unified Protocol for the transdiagnostic treatment of EDs, applied in 5 or 8 group sessions. Finally, the researchers will analyze whether there are specific patient profiles that will benefit more from one or the other condition. The results will contribute to the personalization of the psychological treatment of users with EDs attending PC in the Spanish public health system.",[133,221,222],"Anxiety Disorders","Depressive Disorder",[133,135,224,225,226,227],"Primary Care","Transdiagnostic approach","Group format","Brief format","2025-02-27",{"date":230,"type":39},"2025-03-03",{"date":232,"type":22},"2025-05-10",{"date":234,"type":22},"2027-09-01",{"name":45,"class":46},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":47},"100359271","phase-2-assessment-of-direct-biomarkers-of-aspirin-action-to-develop-a-precision-chemoprevention-therapy-of-colorectal-cancer-100359271","NCT03957902","Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer","Inclusion Criteria:\n\n* age ≥ 18 \\\u003C 80 years old\n* recent diagnosis (\\\u003C 48h) of rectum or colon cancer, established by endoscopy and later confirmed by anatomo-pathologic study\n* normal coagulation values and biochemical vales without clinically significant deviations that, at the discretion of the investigator, may interfere with the study procedures\n\nExclusion Criteria:\n\n* Allergy to ASA or to any other NSAID.\n* Rectal cancer requiring neoadjuvant treatment within the two weeks following the beginning of ASA treatment.\n* Previous use of ASA, NSAIDs, antiplatelet agents, corticosteroids or misoprostol within the 15 days prior to diagnosis and\u002For anticipation of need for treatment with any of these drugs during the study period. History of peptic ulcer disease or active peptic ulcer or any other gastrointestinal disease that may be considered a contraindication to the use of ASA, without the concomitant use of proton pump inhibitors.\n* Diagnosis of bleeding disorders.\n* Diagnosis of cancer (excluding non-melanoma skin cancer) within the previous 3 years.\n* Conditions supposing serious comorbidity, excluding diabetes, and including respiratory, cardiac, hepatic and renal diseases.\n* Active smoking.\n* Pregnancy or breastfeeding.\n* History of drug or alcohol abuse.","79 Years",{"count":244,"type":22},60,[246],"PHASE2","Acetylsalicylic acid (ASA) seems the ideal colorectal cancer (CRC) chemoprevention agent. Several ongoing trials are testing the effect of ASA as co-therapy in CRC. The mechanisms of action, the appropriate dose and the ideal target population are unknown. The investigators have demonstrated that doses of 100 mg of ASA induce direct and partial but persistent acetylation of the cyclooxygenase (COX) isoenzyme COX-1 in the normal colorectal mucosa. The primary objective is to perform a study of aspirin by using a proteomic assay for comparing platelet COX-1 and CRC mucosal COX-1 after different doses of ASA. Secondary objectives are: the measurement of prostaglandin E2 (PGE2) and phosphorylated S6 protein (p-S6) levels in CRC mucosa, the assessment of indirect biomarker of aspirin action (serum thromboxane B2 (TXB2) and urinary levels of 11-dehydro-TXB2 (TX-M)), the evaluation of systemic biomarkers of inflammatory\u002Ftumorigenic COX-2 by assessing urinary levels of major metabolite of PGE2 (PGE-M). Methods: Phase II randomized clinical trial in 60 patients with newly diagnosed CRC in 3 groups of 20 patients receiving 100 or 300 mg\u002Fday, or 100 mg\u002F12 hours of enteric-coated ASA for 3±1 weeks, prior to definitive treatment by surgery. Main outcome: Acetylation of COX-1 and COX-2. Eicosanoid levels in target organs. Expected results: Evidence for the current uncertainty about the mechanisms of action and the dose required to obtain the best chemopreventive effect with ASA in CRC. Confirm acetylation of COX as a key biomarker of efficacy with ASA.",[249],"Colorectal Cancer","2025-02-25",{"date":228,"type":39},{"date":253,"type":39},"2019-05-06",{"date":255,"type":22},"2025-06",{"name":45,"class":46},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":181},"100569740","motor-performance-improvement-after-visual-rehabilitation-100569740","NCT06698172","Motor Performance Improvement After Visual Rehabilitation","Analysis of Motor Performance Improvement Following Visual Rehabilitation Treatment in Individuals with Visual Field Defects Due to Acquired Brain Injury","VRvisual","Inclusion Criteria:\n\n* Adult subjects diagnosed with acquired brain injury either from a stroke or trauma.\n* Subjects without cognitive impairment.\n* Subjects without pre-existing musculoskeletal disorders prior to the acquired brain injury.\n* Subjects without hemineglect.\n* Subjects with more than 6 months of progression since the brain injury.\n* Subjects who have an electronic device such as a computer and internet access to perform the exercises at home.\n* Subjects with altitudinal visual field loss, hemianopia, or quadrantanopia with the central field preserved and at least 0.5 visual acuity.\n\nExclusion Criteria:\n\n* Not signing the informed consent.\n* Previous severe mental pathology to eliminate possible confounding factors if their daily activities are already affected.\n* Uncontrolled epilepsy.\n* Subjects with glaucoma or retinal pathologies affecting the visual field.\n* Subjects with previous ocular surgery (cataract or refractive surgery) with less than 6 months of progression.\n* Subjects who are not stable in any associated clinical pathology or otherwise diagnosed.\n* Subjects who have previously undergone visual rehabilitation for the field defect.\n* Not performing the proposed home exercises.",{"count":266,"type":22},30,[25],"Acquired brain injury\" refers to brain damage that impacts neurological processing, making daily activities challenging and often causing vision issues like binocular dysfunction, oculomotor problems, and visual field loss. In Spain, visual rehabilitation is limited, although it is more common in other countries.\n\nThese patients generally need an interdisciplinary approach involving professionals like physiotherapists and optometrists and often face mobility, balance, and spatial perception difficulties. Treatment tools include lenses, prisms, and technologies like virtual reality (VR). The Visionary VR program, presented by Dr. Portela, has shown promising results in visual field recovery by stimulating the affected area.\n\nVisual rehabilitation is based on brain plasticity and involves three key strategies:\n\nPrisms to expand the visual field. Compensatory therapy to improve eye movement. Restitution therapy to restore the visual field.",[270,271,272,273],"Visual Field Loss","Balance","Brain Injury","Motor Performance","2024-11-18",{"date":276,"type":39},"2024-11-20",{"date":278,"type":22},"2024-11-29",{"date":280,"type":22},"2025-12-31",{"name":45,"class":46},""]